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(year of marketing approval) of OADs. Using observations for 10 years and five
regions, it was possible to estimate a multiple regression model explaining sepa-
rately hospitalizations and hospital costs attributable to diabetes by regional fixed
effects, treated prevalence and the average vintage of OADs. RESULTS: The
results showed that the number of hospitalizations attributable to diabetes are
proportional to the treated prevalence, all else constant, but that the more recent
the OADs used (higher vintage), the lower are hospital admissions (p0.03) and
hospital costs (p0.007). According to the model, if the average vintage of OADs
had increased by one year, the number of admissions would have had a 3.8%
reduction (3965 less episodes in 2009) and hospital costs would have suffered a 5.3%
reduction (about 11 M€ in 2009). CONCLUSIONS: The possible influence of other
difficult to quantify factors notwithstanding, our analysis suggests that in the last
decade the availability of new OADs in the Portuguese market may have played a
key role in the reduction of hospital costs and in-patient admissions attributable to
diabetes.
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OBJECTIVES: Limited data exist on the use of health care resources due to hypo-
glycaemia induced by antidiabetic treatment. This study investigated the occur-
rence of self-reported non-severe hypoglycaemic events (NSHE) in type 1 (T1) and
insulin-treated type 2 (T2) diabetes patients and their impact on health care re-
source use. METHODS: Insulin-treated T1 and T2 patients from Austria, Denmark,
Finland, The Netherlands, Norway, Sweden and Switzerland were invited, primar-
ily via online panels, to complete four questionnaires at weekly intervals. Data
were collected on patient demographics, occurrence of NSHE in the last seven days
and hypoglycaemia-related resource use. NSHE was defined as an event with
symptoms of hypoglycaemia, with or without blood glucose measurement (BGM),
or low BGM without symptoms, which the patient could manage without
assistance. RESULTS: In total, 3958 patients with diabetes entered the study (57%
completing all four questionnaires). T1 and T2 patients experienced a mean of 1.7
and 0.5 events/pt-week. Overall employment rate was 48%. Following the last
NSHE, the proportion of patients contacting a health care professional was 8%
among T2 patients (Austria: 10%, Denmark: 7%, Finland: 10%, Norway: 6%, The
Netherlands: 8%, Sweden: 6%, Switzerland: 14%) and 2% among T1 patients (Aus-
tria: 3%, Denmark: 1%, Finland: 3%, Norway: 2%, The Netherlands: 3%, Sweden: 1%,
Switzerland: 5%). There was a mean increase in BG test use in the week following
the last NSHE of 1.9 across countries (Austria: 2.6, Denmark: 1.3, Finland: 2.1, The
Netherlands: 2.0, Norway: 1.8, Sweden: 1.5, Switzerland: 1.9). Among employed
patients, loss of work-time after the last hypoglycaemic event was reported by 10%
(Austria: 10%, Denmark: 9%, Finland: 17%, The Netherlands: 11%, Norway: 9%, Swe-
den: 12%, Switzerland: 6%). Between countries the average work-time loss among
those losing work-time ranged from 1.3 to 6.7 hours. CONCLUSIONS: NSHE were
associated with use of health care resources and work-time loss in the countries
studied.
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OBJECTIVES: To estimate the health care resource utilization and costs associated
with the management of patients with acromegaly in Québec. METHODS: A retro-
spective cohort study was conducted using data from the Quebec public health
plan (RAMQ) for the period from January 2001 to June 2011. Patients with at least
two diagnosis of acromegaly (ICD92530) reported by an endocrinologist or an
internist were selected. Characteristics of the study population are described in
terms of age, gender and co-morbidities. Health care resources utilization was
estimated, in terms of medical/surgical services, hospitalization, emergency visits
and medications. Costs of these resources were estimated annually over a three-
year period from the time of diagnosis of acromegaly and from the time of specific
intervention (transsphenoidal surgery (TSS) or medical treatment). RESULTS: A
total of 655 patients had at least diagnosis of acromegaly on two occasions reported
by an endocrinologist or an internist. Average age was 49.0(SD19.1) and 55.4%
were females. A pituitary adenoma was reported in 27.0% of patients. During the
study period, TSS was performed for 20.3% of patients while 19,7% had a medical
treatment. Medical therapy included bromocriptine (9.2%), cabergoline (7.6%), oc-
treotide (7.2%), lanreotide (0.5%) and pegvisomant (0.3%). Annual costs for all pa-
tients were $7,203(SD$12,706), $5,038(SD9,545) and $5,266(SD12,291) respec-
tively for each of the three year following initial acromegaly diagnosis. For patients
who had a TSS or a medical treatment, or a combination of these, total cost in the
first year following the initial intervention varies from $9,925 to $17,813. The most
frequent comorbidities were diabetes (47.6%) and hypertension (42.7%). Sleep ap-
nea and carpal tunnel syndrome were reported in 11.1% and 5.3% of patients re-
spectively Average annual costs of medications for the treatment of comorbidities
were $1,454(SD3,338). CONCLUSIONS: Results of this analysis of the RAMQ database
illustrate the significant economic burden of acromegaly and of its comorbidities.
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OBJECTIVES: To estimate the health care resource utilization and costs associated
with Cushing’s disease (CD) in Québec. METHODS: A retrospective cohort study
was conducted using data from the Quebec public health plan (RAMQ) from Janu-
ary 2001 to June 2011. Patients with at least two CD diagnoses (ICD92550) were
initially selected. CD was further confirmed with at least 2 diagnoses of CD reported
by an endocrinologist, or a diagnosis of pituitary adenoma, or a transsphenoidal
surgery (TSS) or a bilateral adrenalectomy (BLA). Health care resources comprise
medical/surgical services, hospitalization, emergency visits and medications.
Costs of these resources were estimated annually over a three-year period from the
time of diagnosis of CD and from the time of specific intervention (TSS, BLA or
medical treatment). RESULTS: Of the 810 patients with two diagnoses of CD, 322
were considered confirmed cases of endogenous CD. The average age was 48.0yrs
(SD16.8) and 72.0% were females. During the study period, TSS and BLA were
performed for 23% and 21.1% of patients respectively while 11.8% had a medical
treatment to control hypercortisolism. Among these patients 5.9% had two inter-
ventions and 0.9% had the three interventions. Annual costs for all patients were
$14,451, $5,737 and $5,679 respectively for each of the three year following initial
CD diagnosis. For patients who had a TSS, or a BLA, or a medical treatment, or a
combination of these, total cost in the first year following the initial intervention
varied from $12,258 to $28,888. The most frequent comorbidities were diabetes
(58.4%), hypertension (57.8%), and osteoporosis (51.2%). Patients had numerous
comorbidities; 85.1% had 2 or more and 69.0% 3 or more. Average annual costs of
medications for the treatment of comorbidities were $2,252 (SD5,713).
CONCLUSIONS: Results of this analysis of the RAMQ database illustrate the signif-
icant economic burden of CD and of its comorbidities.
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OBJECTIVES: To examine the demographic and clinical characteristics in patients
with Cushing’s disease (CD) and to estimate the health care resource utilization
associated in these patients in Ontario. METHODS: Retrospective analysis of re-
source use captured in the Southwestern Ontario Database from 2001 to June 2011.
A total of 86 patients (72% females) were analyzed based on diagnosis, out of a total
population of 523,718 patients. A matched control group (CG) (N86) was also
included from the general population. RESULTS: Age of patients at the time of
diagnosis was 4325.4 years (mean  SD). Baseline co-morbidities (CM) included
hypertension (67.4%), dyslipidemia (25%), diabetes (23.3%), renal calculi (17.4%),
visual disturbance (20.9%), carpal tunnel syndrome (19.8%) and osteoporosis
(11.6%). Distribution of co-morbidities was statistically significantly higher than
general population (p-value 0.05); 27% had 2 CM and 35% had 3 or more CM.
Baseline Urinary Free Cortisol (UFC) level was 207.7 118.3 nmol/day (UFC ULN
110 nmol/day). Primary treatment options included transsphenoidal surgery (TSS),
bilateral adrenalectomy (BLA), radiosurgery and medical therapy, used in 79%, 6%,
2.3% and 12.7% of patients respectively. Secondary treatment was surgical in 37% of
patients: consisting of repeat TSS in 21%, BLA in 10% and RS in 6%, while the
majority received medical therapy (63%). Average length of stay for surgery was 6
days (SD4) and 9 days (SD7) for TSS and BLA respectively. Medical therapy,
prescribed as monotherapy, included ketoconazole (38%), cabergoline (21%), bro-
mocriptine (20%) and mitotane (15%). Health care provider interactions per year for
CD post intervention compared to CG were: Emergency Room visit: 1.01 vs. 0.069;
clinic visits: 4.86 vs. 1.89; specialist clinic visits: 5.57 vs. 0.92; and hospitalizations:
0.34 vs. 0.15.CONCLUSIONS:This retrospective analysis of patients diagnosed with
Cushing’s disease indicates that they require substantially higher resource use and
experience a high burden of comorbidities.
PDB51
RESOURCE UTILIZATION IN THE MANAGEMENT OF ACROMEGALY: AN
ANALYSIS FROM SOUTHWEST ONTARIO
Petrella RJ1, Van uum S1, Hurry M2
1Lawson Health Research Institute, London, ON, Canada, 2Novartis Pharmaceuticals Canada,
Dorval, QC, Canada
OBJECTIVES: To examine the demographic and clinical characteristics in patients
with acromegaly and to estimate the health care resource utilization associated in
these patients in Ontario. METHODS: Retrospective analysis of resource use cap-
tured in the Southwestern Ontario Database from 2001 to June 2011. A total of 131
patients (56% males) were analyzed based on diagnosis, out of a total population of
523,718 patients. A matched control group (CG) (N131) was also included from the
general population. RESULTS: Age of patients at the time of diagnosis was 3525.3
years (mean  SD). Primary treatment options included transsphenoidal surgery
(TSS), radiosurgery and medical therapy, used in 38%, 6% and 56% respectively.
Secondary treatment was surgical in 70% of patients: consisting of repeat TSS in
61% and RS in 9%, while 30% received medical therapy. Average length of stay for
surgery was 88 days in first line TSS. Most frequent post operative complications
(50%) was metabolic-related (81%), gastrointestinal (62%) and fever (38%). Medical
therapy, prescribed as monotherapy, included octreotide (47%), lanreotide (33%),
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